Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03496116
Other study ID # HM20012671
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 21, 2018
Est. completion date December 17, 2018

Study information

Verified date May 2019
Source Virginia Commonwealth University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to measure the individual and combined influence of electronic cigarette (ECIG) heating element resistance and liquid nicotine concentration on ECIG acute effects. Thirty-two experienced ECIG users will complete four independent laboratory sessions that will differ by heater resistance (0.5 ohm or 1.5 ohm) and liquid nicotine concentration (3 or 8 mg/ml). Other factors such as voltage, liquid solvent ratio, and liquid flavor will be held constant. Plasma nicotine concentration, subjective effects, and puffing behavior will be recorded for each condition.


Description:

Electronic cigarettes (ECIGs) are a popular and rapidly evolving class of products. ECIG users can manipulate several device features including liquid nicotine concentration (mg/ml) and heating element resistance (ohms). An emerging class of ECIG models includes "sub-Ohm" devices that employ low resistance heaters that are often used to achieve high device power. Some clinical laboratory data suggest that high power devices deliver nicotine to the user effectively, even when paired with a low liquid nicotine concentration. However, given that ECIG heater resistance and liquid nicotine concentration have not been manipulated in clinical laboratory studies, the influence of these factors on ECIG acute effects remain unclear. The purpose of this clinical laboratory study is to measure the influence of heater resistance and liquid nicotine concentration on ECIG acute effects. Participants will attend the lab for four experimental sessions where they use an ECIG. For each session, the participants will be randomly assigned (like the flip of a coin) to receive an ECIG with one of two different levels of heating coil resistance (which will determine overall device power) and one of two different liquid nicotine concentrations. The four sessions will begin at approximately the same time each day, will be separated by at least 48 hours, and will not occur more than two times per week. The primary hypotheses are that the low resistance heater paired with the 8 mg/ml liquid nicotine concentration, will result in greater nicotine delivery and subjective effect profiles, suggestive of higher abuse potential. Results from this study will further our understanding of the factors that influence the dependence potential of ECIGs and could inform future regulation of these devices.


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date December 17, 2018
Est. primary completion date December 17, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Willing to provide informed consent, attend the lab and abstain from nicotine/tobacco as required, and use designated products according to study protocol

- Experienced ECIG users (use =1 ml of ECIG solution daily, use ECIG solution with a nicotine concentration =3 mg/ml, and have used their ECIG for =3 months)

- Urine cotinine test result = 3

Exclusion Criteria:

- History of organ-related diseases or current psychiatric condition

- Regular use of prescription medication other than vitamins or birth control

- Past month use of cocaine, opioids, benzodiazepines, or methamphetamine

- Using marijuana greater than 10 days in the past 30 and/or alcohol greater than 25 days in the past 30 days

- Pregnant or breastfeeding women

- Weight less than 110 pounds

- Daily use of >5 cigarettes or use of other tobacco products (i.e., hookah, cigars) >3 times a week

Study Design


Related Conditions & MeSH terms


Intervention

Other:
ECIG Session
Participants will complete four sessions using an e-cigarette, including a 10-puff product use bout followed by a 60-minute ad lib bout over an approximately 4-hour period. The study conditions for each session (i.e., heater resistance and nicotine combinations) will be Latin-square ordered.

Locations

Country Name City State
United States Virginia Commonwealth University Richmond Virginia

Sponsors (1)

Lead Sponsor Collaborator
Virginia Commonwealth University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cmax: Plasma nicotine concentration (ng/ml) Six blood samples are collected at each of the 4 visits. During each session, blood samples are collected 90,100,160,185,205,225 minutes into the session which lasts approximately 4 hours.
Secondary Withdrawal suppression: Hughes-Hatsukami Withdrawal Scale Contains 11 items. Administered on a computerized visual analogue scale that consists of a phrase centered on a horizontal line with "not at all" on the left and "extremely" on the right.. Responses range from 0-100. Collected six times at each of the 4 visits. During each session, questions are collected 90,100,160,185,205,225 minutes into the session which lasts approximately 4 hours.
Secondary Withdrawal suppression: Direct effects of nicotine scale Contains 9-items. Administered on a computerized visual analogue scale that consists of a phrase centered on a horizontal line with "not at all" on the left and "extremely" on the right.. Responses range from 0-100. Collected six times at each of the 4 visits. During each session, questions are collected 90,100,160,185,205,225 minutes into the session which lasts approximately 4 hours.
Secondary Withdrawal suppression: Tiffany Drobes Questionnaire of Smoking Urges Contains 10 items. Participants will be asked to rate each phrase on a 7-point scale ranging from 0 (Strongly disagree) to 7 (Strongly agree). The items from this scale will form two factors: Factor 1 (intention to smoke) and Factor 2 (anticipation of relief from abstinence symptoms). Collected six times at each of the 4 visits. During each session, questions are collected 90,100,160,185,205,225 minutes into the session which lasts approximately 4 hours.
Secondary Withdrawal suppression: Direct effects of ECIG use scale Contains 14-items. Administered on a computerized visual analogue scale that consists of a phrase centered on a horizontal line with "not at all" on the left and "extremely" on the right. Responses range from 0-100. Collected six times at each of the 4 visits. During each session, questions are collected 90,100,160,185,205,225 minutes into the session which lasts approximately 4 hours.
Secondary Other subjective effects: General Labeled Magnitude Scale Contains 4-items. This category-ratio scale contains seven semantic labels that increase in sensitivity including: "no sensation", "barely detectable", "weak", "moderate", "strong", "very strong", and "strongest imaginable sensation of any kind." Responses will be coded on a 0-100 scale. Collected six times at each of the 4 visits. During each session, questions are collected 90,100,160,185,205,225 minutes into the session which lasts approximately 4 hours.
Secondary Other subjective effects: Labeled Hedonic Scale Contains 4-items. This category-ratio scale contains ten semantic labels, intended to assess participant liking or disliking of sensations experienced in the general labeled magnitude scale.. Semantic labels include: "most liked sensation imaginable", "like extremely", "like very much", "like moderately", "like slightly", "dislike slightly", "dislike moderately", "dislike very much", "dislike extremely" and "most disliked sensation imaginable". Responses will be coded on a 0-100 scale. Collected six times at each of the 4 visits. During each session, questions are collected 90,100,160,185,205,225 minutes into the session which lasts approximately 4 hours.
Secondary Puff Topography: puff duration Puff duration is the measurement of the length of participant puffs in seconds during a 10-puff directed puffing bout (lasting 5-minutes) and during the 60-minute ad libitum bout where participants are instructed to puff as much or as little as they like on the ECIG. Collected twice at each of the 4 visits. During each session, puff duration is measured at 95 and 225 minutes.
Secondary Puff Topography: puff volume Puff volume is the measurement of the size of participant puffs in milliliters during a 10-puff directed puffing bout (lasting 5-minutes) and during the 60-minute ad libitum bout where participants are instructed to puff as much or as little as they like on the ECIG. Collected twice at each of the 4 visits. During each session, puff duration is measured at 95 and 225 minutes.
Secondary Puff Topography: puff velocity Puff velocity is the measurement of the speed of participant puffs in milliliters per second during a 10-puff directed puffing bout (lasting 5-minutes) and during the 60-minute ad libitum bout where participants are instructed to puff as much or as little as they like on the ECIG. Collected twice at each of the 4 visits. During each session, puff duration is measured at 95 and 225 minutes.
See also
  Status Clinical Trial Phase
Recruiting NCT05176418 - IV Pulsed-Nicotine as a Model of Smoking: The Effects of Dose and Delivery Rate Early Phase 1
Completed NCT04084210 - Impact of Alternative Nicotine-Delivery Products on Combustible Cigarette Use Phase 2
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Withdrawn NCT03707600 - State and Trait Mediated Response to TMS in Substance Use Disorder N/A
Recruiting NCT03999099 - Targeting Orexin to Treat Nicotine Dependence Phase 1
Completed NCT03847155 - Prevention of Nicotine Abstinence in Critically Ill Patients After Major Surgery N/A
Completed NCT02840435 - Study on Sit to Quit Phone Intervention N/A
Completed NCT02139930 - Project 2: Strategies for Reducing Nicotine Content in Cigarettes N/A
Completed NCT01982110 - A Mindfulness Based Application for Smoking Cessation N/A
Completed NCT01926626 - Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers Phase 2
Withdrawn NCT01569477 - Striving to Quit-Wisconsin Tobacco Quit Line N/A
Completed NCT01632189 - The Effect of Varenicline on D2/D3 Receptor Binding in Smokers N/A
Completed NCT01569490 - Striving to Quit: First Breath N/A
Completed NCT01685996 - Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation Phase 1/Phase 2
Active, not recruiting NCT01182766 - New Treatment for Alcohol and Nicotine Dependence Phase 2/Phase 3
Completed NCT00996034 - Nicotine Vaccination and Nicotinic Receptor Occupancy Phase 2
Completed NCT01061528 - Coping Skills Treatment for Smoking Cessation N/A
Withdrawn NCT01589081 - Effects of Progesterone on IV Nicotine-Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effect N/A
Completed NCT01943994 - Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study N/A
Suspended NCT01636336 - Effects of Progesterone on Smoked Nicotine Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effects N/A